Goldman Sachs
ANAC

Goldman Sachs’s ANACOR PHARMACEUTICALS INC COM ANAC Stock Holding History

Goldman Sachs’s Portfolio ANAC Stock Details ANAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-1,561,729
Closed -$83.5M – 7597
2016
Q1 		$83.5M Buy
1,561,729
+1,176,583
+305% +$86.9M 0.03% 763
2015
Q4 		$43.5M Buy
385,146
+275,228
+250% +$30.3M 0.01% 1223
2015
Q3 		$12.9M Buy
109,918
+97,306
+772% +$12.7M ﹤0.01% 2045
2015
Q2 		$976K Sell
12,612
-47,434
-79% -$3.11M ﹤0.01% 4560
2015
Q1 		$3.47M Buy
60,046
+37,293
+164% +$1.58M ﹤0.01% 3247
2014
Q4 		$734K Sell
22,753
-47,924
-68% -$1.44M ﹤0.01% 4898
2014
Q3 		$1.73M Buy
70,677
+19,287
+38% +$392K ﹤0.01% 4082
2014
Q2 		$911K Buy
+51,390
New +$827K ﹤0.01% 4775
2014
Q1 		– Sell
-11,063
Closed -$186K – 7172
2013
Q4 		$186K Buy
+11,063
New +$153K ﹤0.01% 6003
2013
Q3 		– Sell
-13,735
Closed -$77K – 6935
2013
Q2 		$77K Buy
+13,735
New +$83.2K ﹤0.01% 5948

Other funds holding ANAC

KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
CIM
CIM Investment Management Pittsburgh, Pennsylvania $375M AUM 32.03% 1-Year Est. Return

Goldman Sachs's ANAC Position: Q2 2016 in Review

Goldman Sachs sold out of ANACOR PHARMACEUTICALS INC COM (ANAC) in Q2 2016, closing a stake of 1,561,729 shares — an estimated $83.5M sold.

Goldman Sachs first reported a position in ANAC in Q2 2013 and held it in 10 quarters. The position peaked at $83.5M in Q1 2016. 2 funds tracked by Wall St. Rank hold ANAC as of Q2 2016.

  • Goldman Sachs reported no remaining ANACOR PHARMACEUTICALS INC COM position as of Q2 2016 after selling out during the quarter.
  • Goldman Sachs sold 1,561,729 ANACOR PHARMACEUTICALS INC COM shares in Q2 2016, an estimated $83.5M.
  • Goldman Sachs first reported a position in ANACOR PHARMACEUTICALS INC COM in Q2 2013 and held it in 10 quarters.
  • Goldman Sachs's ANACOR PHARMACEUTICALS INC COM position peaked at $83.5M in Q1 2016.
  • 2 funds tracked by Wall St. Rank held ANACOR PHARMACEUTICALS INC COM as of Q2 2016.

Based on Goldman Sachs's 13F filing for Q2 2016, filed 15 Aug 2016.